Ipsen gets Bylvay FDA approval for cholestatic pruritus in Alagille syndrome
The US Food and Drug Administration (FDA) has granted approval to French biopharmaceutical company Ipsen for Bylvay (odevixibat) for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) patients aged 12 months and older. This once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) primarily acts in the small intestine and has minimal systemic exposure. Already […]